Fast Facts: Biosimilars in Hematology and Oncology: Biologics and biosimilars - getting decisions right-Original PDF
Medicine

Fast Facts: Biosimilars in Hematology and Oncology: Biologics and biosimilars – getting decisions right-Original PDF

Login is required

login

If you are not our user, for invitation Click Here

Amazon Price $25

By P. Cornes(Author), A. McBride(Author)

Size : 2.97 MB

Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days’ exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. ‘Fast Facts: Biosimilars in Hematology and Oncology’ provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: • Biologics and the need for biosimilars • Why do we need biosimilars? • How is the quality of biosimilar medicines assured? • Legal issues • Switching, interchangeability and extrapolation • Safety and pharmacovigilant • Global issues • Formulary considerations: pharmacy issues • Formulary considerations: supportive care biosimilars • Formulary considerations: therapeutic anti-cancer biosimilars • Communication and awareness

Product details

  • Series: Fast Facts
  • Paperback: 128 pages
  • Publisher: Health Press in S. Karger AG; 1 edition (January 23, 2020)
  • Language: English
  • ISBN-10: 1912776219
  • ISBN-13: 978-1912776214